Should I Buy NTLA? NTLA 2026 Analysis

Should You Buy Intellia Therapeutics Inc (NTLA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

13.900

1 Day change

0.58%

52 Week Range

28.250

Analysis Updated At

2026/01/26

Intellia Therapeutics Inc (NTLA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant negative sentiment due to safety concerns in its pipeline, insider selling, and a series of downgrades and price target reductions from analysts. Additionally, the technical indicators and options data do not suggest a favorable entry point. The company's financials show revenue growth but worsening net income and EPS, which further weakens the investment case.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. The RSI is neutral at 71.532, and moving averages are converging, showing no clear trend. The stock is trading close to its resistance level (R1: 15.161), with significant downside risk to support levels (S1: 10.714, S2: 9.341). Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a slight bullish sentiment in the options market. However, the implied volatility is high (100.9), and the IV percentile is 82.8, suggesting elevated risk and uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

ARK Invest increased its investments in gene editing firms, which could include NTLA. Revenue increased by 51.27% YoY in Q3 2025.

Neutral/Negative Catalysts

Insider selling has surged by 2235.78% over the last month. The stock has a 40% chance to decline by -13.14% in the next week and -21.01% in the next month.

Financial Performance

In Q3 2025, revenue increased by 51.27% YoY to $13.78M. However, net income dropped by -25.34% YoY to -$101.32M, and EPS fell by -31.34% YoY to -0.92. Gross margin remained flat at 100%. While revenue growth is promising, the worsening profitability metrics are a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have overwhelmingly downgraded the stock recently. Wolfe Research, JonesResearch, Evercore ISI, and others downgraded NTLA, citing safety concerns and lack of clarity in the pipeline. Price targets have been significantly reduced, with some as low as $4. The overall sentiment is negative, with limited optimism for near-term recovery.

22 Analyst Rating

Wall Street analysts forecast NTLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTLA is 16.5 USD with a low forecast of 4 USD and a high forecast of 54 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

12 Hold

1 Sell

Moderate Buy

Current: 13.820

Low

Averages

16.5

High

Current: 13.820

Low

Averages

16.5

High

Baird

Neutral

maintain

$4 -> $7

AI Analysis

2026-01-28

New

Reason

Baird

Price Target

$4 -> $7

AI Analysis

2026-01-28

New

maintain

Neutral

Reason

Baird raised the firm's price target on Intellia Therapeutics to $7 from $4 and keeps a Neutral rating on the shares. The firm updated its model following the lit of the FDA clinical hold for Nex-z hATTR-PN trial.

H.C. Wainwright

Mitchell Kapoor

Buy

maintain

$15 -> $25

2026-01-28

New

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$15 -> $25

2026-01-28

New

maintain

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Intellia Therapeutics to $25 from $15 and keeps a Buy rating on the shares. The FDA signaled that Nex-Z's clinical risk is manageable by lifting the clinical hold, but the market is still pricing in "an existential threat," the analyst tells investors in a research note. The firm upped its probability of approval to 35% from 25%.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NTLA

Unlock Now

NTLA Should I Buy

NTLA Should I Buy

Should You Buy Intellia Therapeutics Inc (NTLA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch